[go: up one dir, main page]

CY1115785T1 - Μακροχρονια θεραπευτικη αγωγη συμπτωματικης καρδιακης ανεπαρκειας - Google Patents

Μακροχρονια θεραπευτικη αγωγη συμπτωματικης καρδιακης ανεπαρκειας

Info

Publication number
CY1115785T1
CY1115785T1 CY20141100980T CY141100980T CY1115785T1 CY 1115785 T1 CY1115785 T1 CY 1115785T1 CY 20141100980 T CY20141100980 T CY 20141100980T CY 141100980 T CY141100980 T CY 141100980T CY 1115785 T1 CY1115785 T1 CY 1115785T1
Authority
CY
Cyprus
Prior art keywords
long term
term treatment
treatment symptoms
heart deficiency
symptom
Prior art date
Application number
CY20141100980T
Other languages
English (en)
Inventor
Claudio Cavazza
Maria Giovanna Caccia
Original Assignee
Spa Societa' Prodotti Antibiotici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spa Societa' Prodotti Antibiotici S.P.A. filed Critical Spa Societa' Prodotti Antibiotici S.P.A.
Publication of CY1115785T1 publication Critical patent/CY1115785T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Heads (AREA)
  • Meat, Egg Or Seafood Products (AREA)

Abstract

Το κύριο αντικείμενο του παρόντος είναι η χρήση ωμέγα-3 πολυακόρεστων λιπαρών οξέων (όπως αιθυλεστέρων, εφεξής «n-3 PUFA») ως φάρμακο, είτε μόνων ή σε συνδυασμό με άλλους θεραπευτικούς παράγοντες, για τη μείωση της θνησιμότητας από καρδιαγγειακή αιτία, ιδίως από αρρυθμία ή για τη μείωση της νοσηλείας για οποιαδήποτε αιτία, ιδίως για καρδιαγγειακή αιτία και για τη χορήγηση σε ημερήσια βάση σε ασθενείς με συμπτωματική καρδιακή ανεπάρκεια (ΚΑ) για περισσότερο από 3.5 χρόνια.
CY20141100980T 2008-08-07 2014-11-26 Μακροχρονια θεραπευτικη αγωγη συμπτωματικης καρδιακης ανεπαρκειας CY1115785T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161994 2008-08-07
EP09777388.1A EP2323647B1 (en) 2008-08-07 2009-07-23 Long-term treatment of symptomatic heart failure

Publications (1)

Publication Number Publication Date
CY1115785T1 true CY1115785T1 (el) 2017-01-25

Family

ID=40101155

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100980T CY1115785T1 (el) 2008-08-07 2014-11-26 Μακροχρονια θεραπευτικη αγωγη συμπτωματικης καρδιακης ανεπαρκειας

Country Status (20)

Country Link
US (1) US8592439B2 (el)
EP (1) EP2323647B1 (el)
JP (1) JP5563573B2 (el)
KR (1) KR20110058775A (el)
CN (1) CN102149376B (el)
AU (1) AU2009278317B2 (el)
BR (1) BRPI0917403A2 (el)
CA (1) CA2732071C (el)
CY (1) CY1115785T1 (el)
DK (1) DK2323647T3 (el)
EA (1) EA020237B1 (el)
ES (1) ES2524596T3 (el)
HR (1) HRP20141149T1 (el)
MX (1) MX2011001419A (el)
PL (1) PL2323647T3 (el)
PT (1) PT2323647E (el)
RS (1) RS53694B1 (el)
SI (1) SI2323647T1 (el)
SM (1) SMT201500019B (el)
WO (1) WO2010015335A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826663A1 (en) 2011-02-07 2012-08-16 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for diastolic congestive heart failure
JP6148255B2 (ja) * 2011-12-27 2017-06-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 早期再入院を低減する方法及びシステム
MX2016015791A (es) * 2014-06-06 2017-05-30 Marine Ingredients Llc Composiciones de omega-3, formas de dosis, y metodos de uso.
WO2019022436A2 (ko) * 2017-07-27 2019-01-31 에리슨제약(주) Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
CN1082909A (zh) 1993-01-03 1994-03-02 潘玉珍 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
US5541225A (en) * 1994-10-11 1996-07-30 The General Hospital Corporation α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia
IT1277953B1 (it) 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
KR20090086078A (ko) * 2006-10-13 2009-08-10 릴라이언트 파마슈티컬스 인코퍼레이티드 항부정맥제 및 오메가-3 지방산 및 이들의 조합 생성물로의 치료

Also Published As

Publication number Publication date
DK2323647T3 (en) 2014-12-08
WO2010015335A1 (en) 2010-02-11
EA201100143A1 (ru) 2011-10-31
JP5563573B2 (ja) 2014-07-30
MX2011001419A (es) 2011-05-25
PL2323647T3 (pl) 2015-03-31
SI2323647T1 (sl) 2015-01-30
US20110178111A1 (en) 2011-07-21
CN102149376B (zh) 2013-12-25
EP2323647B1 (en) 2014-09-10
BRPI0917403A2 (pt) 2015-12-01
EA020237B1 (ru) 2014-09-30
US8592439B2 (en) 2013-11-26
AU2009278317A8 (en) 2011-03-31
EP2323647A1 (en) 2011-05-25
ES2524596T3 (es) 2014-12-10
WO2010015335A8 (en) 2010-04-29
CA2732071A1 (en) 2010-02-11
RS53694B1 (sr) 2015-04-30
PT2323647E (pt) 2014-12-16
AU2009278317B2 (en) 2014-12-18
KR20110058775A (ko) 2011-06-01
HK1160790A1 (en) 2012-08-17
JP2011529928A (ja) 2011-12-15
CA2732071C (en) 2018-02-13
SMT201500019B (it) 2015-03-05
AU2009278317A1 (en) 2010-02-11
HRP20141149T1 (hr) 2015-02-13
CN102149376A (zh) 2011-08-10

Similar Documents

Publication Publication Date Title
CL2021003222A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
HRP20200068T1 (hr) Etilni ester ikozapentaenske kiseline, namijenjen liječenju hipertrigliceridemije
MX2010000224A (es) Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26.
CY1115785T1 (el) Μακροχρονια θεραπευτικη αγωγη συμπτωματικης καρδιακης ανεπαρκειας
TR201908522T4 (tr) Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.
MX2013001749A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
NZ737380A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
RU2017126039A (ru) САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ
ITMI20020269A1 (it) Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
EA200100895A1 (ru) Незаменимые жирные кислоты для предотвращения сердечно-сосудистых приступов
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
Meganathan et al. Evaluation of hepatoprotective effect of omega 3-fatty acid against paracetamol induced liver injury in albino rats
NO20076382L (no) Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer
HRP20110086T1 (hr) Dha esteri i njihova upotreba u tretmanu i prevenciji kardiovaskularnih bolesti
JP2016515530A5 (el)
CR20170320A (es) Mezcla de ácidos carboxílicos para tratar pacientes con insuficiencia renal
TR201808471T4 (tr) Sn-2-monoaçilgliseroller ve lipid malabsorpsiyonu.
JP2007238598A5 (el)
BRPI0512528B8 (pt) uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição
JP2006219454A5 (el)
Broome et al. Mitochondria as nutritional targets to maintain muscle health and physical function during ageing
JP2005047851A5 (el)
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
ES2250397T3 (es) Preparado de combinacion de acidos grasos omega-3 y acidos linoleicos conjugados para el tratamiento de cuadros clinicos de caracter inmunologico.